Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself
- 15 August 2007
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 179 (4), 2493-2500
- https://doi.org/10.4049/jimmunol.179.4.2493
Abstract
Established widely metastatic tumor was cured in a transplanted mouse B cell lymphoma model, by the combination of chemotherapy plus intratumoral injection of oligodeoxynucleotides containing unmethylated C-G motifs (CpG). This therapeutic effect required that the CpG be injected directly into the tumor and was dependent on CD8 T cells. Although the efficacy of CpG oligodeoxynucleotides has been thought to depend on the expression of TLR9, we unexpectedly found that tumor rejection did not require host expression of TLR9. By using a TLR9-deficient tumor and a TLR9KO host, we demonstrate that TLR9 expression either by the host or the tumor is required. These results indicate that activation of Ag presentation by cells within the tumor via TLR9 stimulation can be an effective form of immunotherapy. This study forms the basis of an ongoing clinical trial in patients with lymphoma.Keywords
This publication has 41 references indexed in Scilit:
- Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin LymphomaJournal of Immunotherapy, 2006
- Comparative analysis of antitumor activity of CD40L, RANKL, and 4‐1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cellsThe Journal of Gene Medicine, 2005
- Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamideBlood, 2005
- Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activityJournal of Leukocyte Biology, 2004
- CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curativeEuropean Journal of Immunology, 2004
- Cross-priming of CD8+ T cells stimulated by virus-induced type I interferonNature Immunology, 2003
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- Consequences of Cell DeathThe Journal of Experimental Medicine, 2000
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994
- Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?Immunology Today, 1994